199 related articles for article (PubMed ID: 25434354)
1. KSP inhibitors as antimitotic agents.
Pérez-Melero C
Curr Top Med Chem; 2014; 14(20):2286-311. PubMed ID: 25434354
[TBL] [Abstract][Full Text] [Related]
2. Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP.
Coleman PJ; Schreier JD; Cox CD; Fraley ME; Garbaccio RM; Buser CA; Walsh ES; Hamilton K; Lobell RB; Rickert K; Tao W; Diehl RE; South VJ; Davide JP; Kohl NE; Yan Y; Kuo L; Prueksaritanont T; Li C; Mahan EA; Fernandez-Metzler C; Salata JJ; Hartman GD
Bioorg Med Chem Lett; 2007 Oct; 17(19):5390-5. PubMed ID: 17761419
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
Kaan HY; Ulaganathan V; Rath O; Prokopcová H; Dallinger D; Kappe CO; Kozielski F
J Med Chem; 2010 Aug; 53(15):5676-83. PubMed ID: 20597485
[TBL] [Abstract][Full Text] [Related]
4. Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors.
Nagarajan S; Skoufias DA; Kozielski F; Pae AN
J Med Chem; 2012 Mar; 55(6):2561-73. PubMed ID: 22309208
[TBL] [Abstract][Full Text] [Related]
5. Progress on kinesin spindle protein inhibitors as anti-cancer agents.
Zhang Y; Xu W
Anticancer Agents Med Chem; 2008 Aug; 8(6):698-704. PubMed ID: 18690830
[TBL] [Abstract][Full Text] [Related]
6. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
Cox CD; Garbaccio RM
Anticancer Agents Med Chem; 2010 Nov; 10(9):697-712. PubMed ID: 21235439
[TBL] [Abstract][Full Text] [Related]
7. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
[TBL] [Abstract][Full Text] [Related]
8. Target driven preclinical screening for new antimitotic chemotherapy agents.
Novío S; Freire-Garabal M; Núñez MJ
Curr Top Med Chem; 2014; 14(20):2263-71. PubMed ID: 25434356
[TBL] [Abstract][Full Text] [Related]
9. New chemical tools for investigating human mitotic kinesin Eg5.
Klein E; DeBonis S; Thiede B; Skoufias DA; Kozielski F; Lebeau L
Bioorg Med Chem; 2007 Oct; 15(19):6474-88. PubMed ID: 17587586
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological evaluation and molecular docking studies of flavone and isoflavone derivatives as a novel class of KSP (kinesin spindle protein) inhibitors.
Dong JJ; Li QS; Liu ZP; Wang SF; Zhao MY; Yang YH; Wang XM; Zhu HL
Eur J Med Chem; 2013; 70():427-33. PubMed ID: 24184776
[TBL] [Abstract][Full Text] [Related]
11. Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP.
Roecker AJ; Coleman PJ; Mercer SP; Schreier JD; Buser CA; Walsh ES; Hamilton K; Lobell RB; Tao W; Diehl RE; South VJ; Davide JP; Kohl NE; Yan Y; Kuo LC; Li C; Fernandez-Metzler C; Mahan EA; Prueksaritanont T; Hartman GD
Bioorg Med Chem Lett; 2007 Oct; 17(20):5677-82. PubMed ID: 17766111
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of biphenyl compounds as kinesin spindle protein inhibitors.
Holland JP; Kang A; Cohrs S; Selivanova SV; Milicevic Sephton S; Betzel T; Frey D; Wieser M; Jaussi R; Kammerer RA; Schibli R; Fischer E
Chem Biodivers; 2013 Apr; 10(4):538-55. PubMed ID: 23576341
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of N-(1-(6-acetamido-5-phenylpyrimidin-4-yl) piperidin-3-yl) amide derivatives as potential inhibitors for mitotic kinesin spindle protein.
Muthuraja P; Himesh M; Prakash S; Venkatasubramanian U; Manisankar P
Eur J Med Chem; 2018 Mar; 148():106-115. PubMed ID: 29454915
[TBL] [Abstract][Full Text] [Related]
14. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP.
Rickert KW; Schaber M; Torrent M; Neilson LA; Tasber ES; Garbaccio R; Coleman PJ; Harvey D; Zhang Y; Yang Y; Marshall G; Lee L; Walsh ES; Hamilton K; Buser CA
Arch Biochem Biophys; 2008 Jan; 469(2):220-31. PubMed ID: 17999913
[TBL] [Abstract][Full Text] [Related]
15. Multicomponent reactions in antimitotic drug discovery.
Cores A; Carbajales C; Coelho A
Curr Top Med Chem; 2014; 14(20):2209-30. PubMed ID: 25440494
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in discovery and development of antimitotic agents.
Kiselyov A; Balakin KV; Tkachenko SE; Savchuk N; Ivachtchenko AV
Anticancer Agents Med Chem; 2007 Mar; 7(2):189-208. PubMed ID: 17348827
[TBL] [Abstract][Full Text] [Related]
17. Role of KSP Inhibitors as Anti-cancer Therapeutics: An Update.
Chamariya R; Suvarna V
Anticancer Agents Med Chem; 2022; 22(14):2517-2538. PubMed ID: 35043768
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel EG5 inhibitors.
Sarli V; Huemmer S; Sunder-Plassmann N; Mayer TU; Giannis A
Chembiochem; 2005 Nov; 6(11):2005-13. PubMed ID: 16216042
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents.
Gangjee A; Zhao Y; Hamel E; Westbrook C; Mooberry SL
J Med Chem; 2011 Sep; 54(17):6151-5. PubMed ID: 21786793
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents.
Muthuraja P; Veeramani V; Prakash S; Himesh M; Venkatasubramanian U; Manisankar P
Bioorg Chem; 2019 Mar; 84():493-504. PubMed ID: 30594885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
